Can drugs influencing the renin-angiotensin system prevent diabetes mellitus? a lesson from randomized clinical trials

Cardiology Journal

Volumn 17, Issue 5, 2010, Pages 435-436

  Filipiak, Krzysztof J ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG RESPONSE; EDITORIAL; GLUCOSE INTOLERANCE; HUMAN; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 77957947390     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (6)

1. Al-Mallah M, Khawaja O, Sinno M et al. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent dia- betes mellitus? A meta-analysis. Cardiol J, 2010; 17: 448-456.
2. Yusuf S, Teo KK, Pogue J et al.; for ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascu- lar events. N Engl J Med, 358: 1547-1559.
3. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med, 2000; 342: 145-153.
4. Dagenais GR, Gerstein HC, Holman R et al.; DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovas-cular and renal outcomes in people with impaired glucose toler-ance or impaired fasting glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medica-tion (DREAM) trial. Diabetes Care, 2008; 31: 1007-1014.
5. Schupp M, Janke J, Classen R et al. Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor--gamma activity. Circulation, 2004; 109: 2054-2057.
6. McMurray JJ, Holman RR, Haffner SM et al.; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010; 362: 1477-1490.